Akero Therapeutics to Present at the BofA Securities 2025 Healthcare Conference
Akero Therapeutics (NASDAQ: AKRO), a clinical-stage biotech company focused on developing treatments for serious metabolic diseases, has announced its participation in the upcoming BofA Securities 2025 Healthcare Conference. The company's management will deliver a presentation on Tuesday, May 13, 2025, at 1:40 p.m. Pacific Time. Investors and interested parties can access the live webcast through Akero's investor relations website at www.akerotx.com, where an archived replay will also be available after the presentation.
Akero Therapeutics (NASDAQ: AKRO), una società biotech in fase clinica specializzata nello sviluppo di trattamenti per gravi malattie metaboliche, ha annunciato la sua partecipazione al prossimo BofA Securities 2025 Healthcare Conference. Il management dell'azienda terrà una presentazione il martedì 13 maggio 2025, alle 13:40 ora del Pacifico. Investitori e interessati potranno seguire la diretta streaming tramite il sito web delle relazioni con gli investitori di Akero all'indirizzo www.akerotx.com, dove sarà disponibile anche una registrazione dell'evento dopo la presentazione.
Akero Therapeutics (NASDAQ: AKRO), una empresa biotecnológica en etapa clínica enfocada en desarrollar tratamientos para enfermedades metabólicas graves, ha anunciado su participación en la próxima Conferencia de Salud BofA Securities 2025. La dirección de la compañía realizará una presentación el martes 13 de mayo de 2025 a la 1:40 p.m. hora del Pacífico. Los inversores y personas interesadas podrán acceder a la transmisión en vivo a través del sitio web de relaciones con inversores de Akero en www.akerotx.com, donde también estará disponible una repetición archivada después de la presentación.
Akero Therapeutics (NASDAQ: AKRO)는 심각한 대사 질환 치료제 개발에 주력하는 임상 단계 바이오테크 기업으로, 다가오는 BofA Securities 2025 Healthcare Conference에 참여할 것이라고 발표했습니다. 회사 경영진은 2025년 5월 13일 화요일 오후 1시 40분 태평양 시간에 발표를 진행할 예정입니다. 투자자 및 관심 있는 분들은 Akero 투자자 관계 웹사이트 www.akerotx.com을 통해 라이브 웹캐스트를 시청할 수 있으며, 발표 후에는 녹화된 다시보기 영상도 제공됩니다.
Akero Therapeutics (NASDAQ : AKRO), une société biotechnologique en phase clinique spécialisée dans le développement de traitements pour les maladies métaboliques graves, a annoncé sa participation à la prochaine conférence BofA Securities Healthcare 2025. La direction de l'entreprise présentera le mardi 13 mai 2025 à 13h40, heure du Pacifique. Les investisseurs et les personnes intéressées pourront accéder à la diffusion en direct via le site des relations investisseurs d'Akero à l'adresse www.akerotx.com, où un replay sera également disponible après la présentation.
Akero Therapeutics (NASDAQ: AKRO), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von Behandlungen für schwere Stoffwechselerkrankungen spezialisiert hat, hat seine Teilnahme an der bevorstehenden BofA Securities 2025 Healthcare Conference angekündigt. Das Management des Unternehmens wird am Dienstag, den 13. Mai 2025, um 13:40 Uhr Pazifischer Zeit eine Präsentation halten. Investoren und Interessierte können den Live-Webcast über die Investor-Relations-Website von Akero unter www.akerotx.com verfolgen, wo auch eine Aufzeichnung nach der Präsentation verfügbar sein wird.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at the BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025, at 1:40 p.m. P.T.
A live webcast of the Company presentation will be available through the investor relations section of the Company's website at www.akerotx.com. Following the live webcast, an archived replay will be available on the Company's website.
About Akero Therapeutics
Akero Therapeutics is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including metabolic dysfunction-associated steatohepatitis (MASH). Akero’s lead product candidate, efruxifermin (EFX), is currently being evaluated in three ongoing Phase 3 clinical studies: SYNCHRONY Histology in patients with pre-cirrhotic (F2-F3 fibrosis) MASH, SYNCHRONY Outcomes in patients with compensated cirrhosis (F4) due to MASH, and SYNCHRONY Real-World in patients with MASH or MASLD (Metabolic Dysfunction Associated Steatotic Liver Disease). The Phase 3 SYNCHRONY program builds on the results of two Phase 2b clinical trials, the HARMONY study in patients with pre-cirrhotic MASH and the SYMMETRY study in patients with compensated cirrhosis due to MASH. Akero is headquartered in South San Francisco. Visit us at akerotx.com and follow us on LinkedIn and X for more information.
Investor Contact:
Christina Tartaglia
Precision AQ
332.322.7430
Christina.tartaglia@precisionaq.com
Media Contact:
Peg Rusconi
617.910.6217
peg.rusconi@deerfieldgroup.com
FAQ
When is Akero Therapeutics (AKRO) presenting at the BofA Securities Healthcare Conference 2025?
How can I watch Akero Therapeutics' (AKRO) presentation at the BofA Securities conference?
What type of company is Akero Therapeutics (AKRO)?
Where can I find the replay of Akero Therapeutics' (AKRO) BofA Securities conference presentation?
